121 related articles for article (PubMed ID: 38242766)
21. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
Primrose J; Falk S; Finch-Jones M; Valle J; O'Reilly D; Siriwardena A; Hornbuckle J; Peterson M; Rees M; Iveson T; Hickish T; Butler R; Stanton L; Dixon E; Little L; Bowers M; Pugh S; Garden OJ; Cunningham D; Maughan T; Bridgewater J
Lancet Oncol; 2014 May; 15(6):601-11. PubMed ID: 24717919
[TBL] [Abstract][Full Text] [Related]
22. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.
Tie J; Cohen JD; Lahouel K; Lo SN; Wang Y; Kosmider S; Wong R; Shapiro J; Lee M; Harris S; Khattak A; Burge M; Harris M; Lynam J; Nott L; Day F; Hayes T; McLachlan SA; Lee B; Ptak J; Silliman N; Dobbyn L; Popoli M; Hruban R; Lennon AM; Papadopoulos N; Kinzler KW; Vogelstein B; Tomasetti C; Gibbs P;
N Engl J Med; 2022 Jun; 386(24):2261-2272. PubMed ID: 35657320
[TBL] [Abstract][Full Text] [Related]
23. Oxaliplatin (3 months
Kim ST; Kim SY; Lee J; Yun SH; Kim HC; Lee WY; Kim TW; Hong YS; Lim SB; Baek JY; Oh JH; Ahn JB; Shin SJ; Han SW; Kim SG; Kang SY; Sym SJ; Zang DY; Kim YH; Choi IS; Kang JH; Kim MJ; Park YS
J Clin Oncol; 2022 Nov; 40(33):3868-3877. PubMed ID: 35772045
[TBL] [Abstract][Full Text] [Related]
24. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
Diefenhardt M; Ludmir EB; Hofheinz RD; Ghadimi M; Minsky BD; Rödel C; Fokas E
JAMA Oncol; 2020 Sep; 6(9):1416-1421. PubMed ID: 32644104
[TBL] [Abstract][Full Text] [Related]
25. Postoperative adjuvant chemotherapy in rectal cancer operated for cure.
Petersen SH; Harling H; Kirkeby LT; Wille-Jørgensen P; Mocellin S
Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD004078. PubMed ID: 22419291
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer.
Kahn KL; Adams JL; Weeks JC; Chrischilles EA; Schrag D; Ayanian JZ; Kiefe CI; Ganz PA; Bhoopalam N; Potosky AL; Harrington DP; Fletcher RH
JAMA; 2010 Mar; 303(11):1037-45. PubMed ID: 20233821
[TBL] [Abstract][Full Text] [Related]
27. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant Capecitabine and Oxaliplatin for Elderly Patients with Colorectal Cancer.
Okamoto K; Nozawa H; Emoto S; Murono K; Sasaki K; Ishihara S
Oncology; 2022; 100(11):576-582. PubMed ID: 36252550
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
Goéré D; Benhaim L; Bonnet S; Malka D; Faron M; Elias D; Lefèvre JH; Deschamps F; Dromain C; Boige V; Dumont F; De Baere T; Ducreux M
Ann Surg; 2013 Jan; 257(1):114-20. PubMed ID: 23235397
[TBL] [Abstract][Full Text] [Related]
30. Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.
Vernieri C; Galli F; Ferrari L; Marchetti P; Lonardi S; Maiello E; Iaffaioli RV; Zampino MG; Zaniboni A; De Placido S; Banzi M; Damiani A; Ferrari D; Rosati G; Labianca RF; Bidoli P; Frassineti GL; Nicolini M; Pavesi L; Tronconi MC; Buonadonna A; Ferrario S; Re GL; Adamo V; Tamburini E; Clerico M; Giordani P; Leonardi F; Barni S; Ciarlo A; Cavanna L; Gori S; Cinieri S; Faedi M; Aglietta M; Antista M; Dotti KF; Galli F; Di Bartolomeo M;
Oncologist; 2019 Mar; 24(3):385-393. PubMed ID: 30606884
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Salem ME; Yin J; Goldberg RM; Pederson LD; Wolmark N; Alberts SR; Taieb J; Marshall JL; Lonardi S; Yoshino T; Kerr RS; Yothers G; Grothey A; Andre T; De Gramont A; Shi Q
Ann Oncol; 2020 Apr; 31(4):480-486. PubMed ID: 32085892
[TBL] [Abstract][Full Text] [Related]
32. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
33. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
André T; Meyerhardt J; Iveson T; Sobrero A; Yoshino T; Souglakos I; Grothey A; Niedzwiecki D; Saunders M; Labianca R; Yamanaka T; Boukovinas I; Vernerey D; Meyers J; Harkin A; Torri V; Oki E; Georgoulias V; Taieb J; Shields A; Shi Q
Lancet Oncol; 2020 Dec; 21(12):1620-1629. PubMed ID: 33271092
[TBL] [Abstract][Full Text] [Related]
34. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.
Wasan HS; Gibbs P; Sharma NK; Taieb J; Heinemann V; Ricke J; Peeters M; Findlay M; Weaver A; Mills J; Wilson C; Adams R; Francis A; Moschandreas J; Virdee PS; Dutton P; Love S; Gebski V; Gray A; ; ; ; van Hazel G; Sharma RA
Lancet Oncol; 2017 Sep; 18(9):1159-1171. PubMed ID: 28781171
[TBL] [Abstract][Full Text] [Related]
35. Real-world tolerance and outcomes of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer-Does dose intensity matter?
Yoon R; Wilkinson K; Gabriel G; Kadaan N; Roberts T; Lim S; Asghari R; Lee CS; Chua W; Ng W
Asia Pac J Clin Oncol; 2024 Feb; 20(1):63-70. PubMed ID: 37211922
[TBL] [Abstract][Full Text] [Related]
36. The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: a multicentered retrospective analysis.
Breadner D; Loree JM; Cheung WY; Gipson M; Lakkunarajah S; Mulder KE; Spartlin JL; Kong S; Ding PQ; Gill S; Welch SA
BMC Cancer; 2022 Nov; 22(1):1119. PubMed ID: 36319973
[TBL] [Abstract][Full Text] [Related]
37. Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer.
Abrams TA; Brightly R; Mao J; Kirkner G; Meyerhardt JA; Schrag D; Fuchs CS
J Clin Oncol; 2011 Aug; 29(24):3255-62. PubMed ID: 21768462
[TBL] [Abstract][Full Text] [Related]
38. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
Snoeren N; Voest EE; Bergman AM; Dalesio O; Verheul HM; Tollenaar RA; van der Sijp JR; Schouten SB; Rinkes IH; van Hillegersberg R
BMC Cancer; 2010 Oct; 10():545. PubMed ID: 20937118
[TBL] [Abstract][Full Text] [Related]
39. Neurotoxicity Outcomes in a Population-based Cohort of Elderly Patients Treated With Adjuvant Oxaliplatin for Colorectal Cancer.
Raphael MJ; Fischer HD; Fung K; Austin PC; Anderson GM; Booth CM; Singh S
Clin Colorectal Cancer; 2017 Dec; 16(4):397-404.e1. PubMed ID: 28434884
[TBL] [Abstract][Full Text] [Related]
40. Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer.
Loree JM; Sha A; Soleimani M; Kennecke HF; Ho MY; Cheung WY; Mulder KE; Abadi S; Spratlin JL; Gill S
Clin Colorectal Cancer; 2018 Jun; 17(2):156-163. PubMed ID: 29486916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
